首页> 外文期刊>Canadian Journal of Physiology and Pharmacology >Comparative evaluation of atenolol and metoprolol on cardiovascular complications associated with streptozotocin-induced diabetic rats.
【24h】

Comparative evaluation of atenolol and metoprolol on cardiovascular complications associated with streptozotocin-induced diabetic rats.

机译:阿替洛尔和美托洛尔对链脲佐菌素诱发的糖尿病大鼠心血管并发症的比较评价。

获取原文
获取原文并翻译 | 示例
           

摘要

Recently, various clinical studies have indicated that lipophilic beta-blockers reduce the coronary mortality in diabetic patients; however, systematic studies have not been reported. The objective of the present investigation was to compare the effects of chronic treatment with metoprolol and atenolol on cardiovascular complications in streptozotocin (STZ)-induced diabetic rats. Injection of STZ produced hyperglycemia, hypoinsulinemia, hyperlipidemia, increased blood pressure, cardiac hypertrophy, reduction in heart rate, and structural alterations in cardiac tissues. Metoprolol and atenolol effectively prevented the development of hypertension in diabetic rats. Metoprolol treatment produced a slight but significant reduction in serum glucose levels with elevation in serum insulin levels, while atenolol produced a slight increase in glucose levels but no effect on insulin levels. Moreover, neither metoprolol nor atenolol treatment reduced the elevated cholesterol levels in diabetic rats. Metoprolol treatment significantly prevented STZ-induced increase in triglyceride levels, but atenolol failed to produce this effect. Metoprolol exhibited a minimal improvement in STZ-induced bradycardia, whereas atenolol produced a further reduction in heart rate. Histological examination showed metoprolol treatment also prevented STZ-induced hypertrophy and some of the alterations in cardiomyocytes. In conclusion, our data suggest that metoprolol has some beneficial effects over atenolol with respect to cardiovascular complications associated with diabetes mellitus.
机译:最近,各种临床研究表明,亲脂性β受体阻滞剂可降低糖尿病患者的冠状动脉死亡率。但是,尚未有系统的研究报道。本研究的目的是比较长期用美托洛尔和阿替洛尔治疗对链脲佐菌素(STZ)诱导的糖尿病大鼠心血管并发症的影响。注射STZ会产生高血糖,低胰岛素血症,高脂血症,血压升高,心脏肥大,心率降低和心脏组织结构改变。美托洛尔和阿替洛尔可有效预防糖尿病大鼠高血压的发展。美托洛尔治疗会随着血清胰岛素水平的升高而使血糖水平略微但显着降低,而阿替洛尔的血糖水平则略有升高,但对胰岛素水平没有影响。而且,美托洛尔和阿替洛尔都不能降低糖尿病大鼠胆固醇水平的升高。美托洛尔治疗显着阻止了STZ诱导的甘油三酸酯水平升高,但阿替洛尔未能产生这种作用。美托洛尔在STZ诱发的心动过缓方面显示出最小的改善,而阿替洛尔则使心率进一步降低。组织学检查显示,美托洛尔治疗还预防了STZ引起的肥大和心肌细胞的某些改变。总之,我们的数据表明,在糖尿病相关的心血管并发症方面,美托洛尔优于阿替洛尔。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号